Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a deal worth up to $1.36 billion.

2025 could easily be yet another year when Eli Lilly dwarfs the S&P 500. A potentially huge catalyst on the way Keith Speights (Summit Therapeutics): To say that Summit Therapeutics stock trounced ...

CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious ...